RxDoctor Payments Data

Catherine Cannan, APRN

Adult Health · New Britain, CTNPI 1740821115

Payments from drug & device makers

$3,565in general payments, 2019–2025

Across 66 payments — averaging $54.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$634
  • E.r. Squibb & Sons, L.L.C.$527
  • AstraZeneca$410
  • Beigene USA, Inc.$233
  • AbbVie$229
  • Incyte Corporation$186
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$1153%
  • Food & beverage$2,81379%
  • Education$63818%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,565 in reported general payments places this provider in the 80th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Medicare billing

Part B allowed, 2024
$26,110
Medicare patients
145
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide29$535,671
XareltoRivaroxaban77$63,900
EliquisApixaban97$62,815
Oxycodone Hcl66$1,545
Ondansetron OdtOndansetron59$747
Morphine Sulfate12$661
Fentanyl11$640
Anastrozole49$619
Gabapentin64$614
Famotidine42$552
Hydroxyurea19$548
Tamoxifen Citrate23$509
Morphine Sulfate ErMorphine Sulfate12$447
Dexamethasone36$440
Acyclovir24$436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$174$535,67129 claims
Johnson & JohnsonXarelto$634$63,90077 claims
PfizerEliquis$62$62,81597 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 418 adult health providers in Connecticut.

Other adult health in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →